Studies

Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Liver international : official journal of the International Association for the Study of the Liver|2025|Petta S et al.

Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that s…

ReviewSemaglutide

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States.

ClinicoEconomics and outcomes research : CEOR|2025|Kim Y et al.

BACKGROUND: Interim results from the ESSENCE clinical trials indicate that 72-week treatment with high-dose subcutaneous (SC) semaglutide may result in metabolic dysfunction-associated steatohepatitis (MASH) resolution and improvements in fibrosis. A…

Semaglutide

PMID: 41147033

The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.

PloS one|2025|Norlin J et al.

Fibroblast growth factor 21 (FGF21) analogs have significant therapeutic potential in metabolic dysfunction-associated steatohepatitis (MASH) but limited body weight effects in patients with MASH. This study investigated the effect of combined treatm…

Animal StudySemaglutide

PMID: 41150667

Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.

Diabetes & metabolic syndrome|2025|Veronese N et al.

AIMS: This umbrella review synthesized evidence from systematic reviews and meta-analyses of randomized controlled trials (RCTs) to assess the effectiveness of interventions for preventing adverse outcomes in individuals with prediabetes. METHODS: A…

ReviewSemaglutide

PMID: 41151201

Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs.

Nature communications|2025|Colston K, Faivre K, Schneebeli S

The passive membrane permeation of small-molecule drugs and small hydrophobic peptides is relatively well understood. In contrast, how long polar peptides can pass through a membrane has remained a mystery. This process can be achieved with permeatio…

Semaglutide

PMID: 41152279

GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.

International journal of molecular sciences|2025|Sardu C et al.

The aim was to assess the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RA) treatment on the progression of ascending aorta dilatation in patients with type 2 diabetes mellitus (T2DM). A total of 127 T2DM patients with subclinical ascend…

Semaglutide

PMID: 41155271

Semaglutide After Catheter Ablation: A New Chapter in Atrial Fibrillation Care?

Circulation. Arrhythmia and electrophysiology|2025|Middeldorp M, Shahmohamadi E

Semaglutide

PMID: 41159264

Liraglutide for adults living with obesity.

The Cochrane database of systematic reviews|2025|Meza N et al.

RATIONALE: Obesity is a complex chronic condition linked to various comorbidities, such as hypertension, diabetes, and dyslipidaemia, with a significant global burden. Standard treatments, such as diet modifications and physical activity, often have…

ReviewMeta-AnalysisSemaglutide

PMID: 41161684

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.

BMJ open diabetes research & care|2025|Kattinakere Sreedhara S et al.

OBJECTIVE: Using national claims databases, we sought to emulate the design of the ongoing SEPRA trial and predict its findings, comparing the effects of once weekly semaglutide to SoC medications on glycemic control (A1C <7%) in type-2 diabetes mell…

Clinical TrialSemaglutide

PMID: 41161770

Chemoenzymatic Synthesis of Rhamnolipid-Modified Exendin-4: A Dual Approach for Long-Acting Glycemic Control through Endogenous Antibody Recruitment and Albumin Interaction.

Journal of medicinal chemistry|2025|Dai S et al.

Effective management of Type 2 diabetes requires therapies that balance potency with sustained action. Glycosylation of glucagon-based drugs improves stability and reduces aggregation but does not significantly enhance pharmacokinetics. This study de…

Animal StudySemaglutide

PMID: 41163197

Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.

Journal of the Endocrine Society|2025|Joly A et al.

Animals rely on linear growth to attain their full adult size. The regulators of this multifactorial process, including environmental and endocrine cues, are still incompletely understood. Notably, GLP-1, glucagon-like peptide 1 (GLP-1) has emerged a…

Animal StudySemaglutide

PMID: 41163813

Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.

JBRA assisted reproduction|2025|Piazza M

Polycystic ovary syndrome (PCOS) is a widespread condition affecting women of reproductive age. A new class of medications called incretins (GLP1RAs) provides new opportunities for reducing obesity, hyperandrogenism, and insulin resistance in these p…

ReviewSemaglutide

PMID: 41165218

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.

Addiction science & clinical practice|2025|Freet C et al.

BACKGROUND: Standard medications for opioid use disorder (MOUD) provide effective treatment pathways for recovery compared with no treatment or behavioral therapies alone. That said, people who continue to use non-prescribed opioids despite treatment…

Semaglutide

PMID: 41168808

Semaglutide-associated psychiatric disorders: A case report and literature review.

Endocrinologia, diabetes y nutricion|2025|Escolà-Rodríguez A et al.

Case ReportSemaglutide

PMID: 41173570

Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.

World journal of hepatology|2025|Niu S et al.

BACKGROUND: The molecular mechanisms associated with semaglutide and empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) still require further studies to develop precise therapeutic strategies. AIM: To investigate the ef…

Animal StudySemaglutide

PMID: 41179732

Off-label ozempic and pancreatitis: legitimate concern or overblown fear?

Annals of medicine and surgery (2012)|2025|Ajmal H et al.

Semaglutide

PMID: 41180652

From prescription to trend: the misuse of Ozempic in the age of social media.

Annals of medicine and surgery (2012)|2025|Muhammad H, Cheema A

Semaglutide

PMID: 41181496

Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.

Molecular biology reports|2025|Wang Q et al.

BACKGROUND: Renal ischemia-reperfusion injury (RIRI) is a major cause of acute kidney injury, with endothelial dysfunction playing a central role in its pathophysiology. However, the molecular mechanisms underlying endothelial damage during RIRI rema…

Semaglutide

PMID: 41186784

Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy.

Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States.

The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.

Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.

Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs.

GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.

Semaglutide After Catheter Ablation: A New Chapter in Atrial Fibrillation Care?

Liraglutide for adults living with obesity.

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.

From MRI to Ozempic: breakthroughs that show why fundamental research must be protected.

Chemoenzymatic Synthesis of Rhamnolipid-Modified Exendin-4: A Dual Approach for Long-Acting Glycemic Control through Endogenous Antibody Recruitment and Albumin Interaction.

Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.

Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.

Semaglutide-associated psychiatric disorders: A case report and literature review.

Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.

Off-label ozempic and pancreatitis: legitimate concern or overblown fear?

From prescription to trend: the misuse of Ozempic in the age of social media.

Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.